
Join to view full profile
5330 South 900 EastSuite 120Salt Lake City, UT 84117
Phone+1 801-266-0055
Fax+1 801-266-0056
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 6 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Mehregan, MD is a board certified dermatologist in Salt Lake City, Utah. He is currently licensed to practice medicine in Utah, Arizona, and Iowa. He is affiliated with Intermountain Medical Center, Alta View Hospital, and LDS Hospital.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Dermatopathology, 1990 - 1991
Mayo Clinic College of Medicine and Science (Rochester)Residency, Dermatology, 1987 - 1990
Corewell Health East Beaumont (Royal Oak)Internship, Transitional Year, 1986 - 1987
Wayne State University School of MedicineClass of 1982
Certifications & Licensure
UT State Medical License 2005 - 2028
OH State Medical License 1991 - 2021
AZ State Medical License 2011 - 2020
IA State Medical License 2011 - 2020
ID State Medical License 2011 - 2020
IL State Medical License 2011 - 2020
NY State Medical License 2011 - 2020
American Board of Dermatology Dermatology
American Board of Dermatology Dermatopathology- Join now to see all
Publications & Presentations
PubMed
- 4 citationsInterstitial granulomatous dermatitis and palisaded neutrophilic granulomatous dermatitis.Taryn Huizenga, Jessica Kado, Brenda L Pellicane, Judy H. Borovicka, Darius R. Mehregan
Cutis. 2018-05-01 - Itchy bumps with new-onset bullae.Syed Hamzah Mahmood, Anthony Van Vreede, David A. Mehregan
Pediatric Dermatology. 2018-01-01 - 2 citationsSacral zoster with a primary complaint of difficulty voidingJeremy A. Grekin, David A. Mehregan
JAAD Case Reports. 2017-11-01
Press Mentions
Pulse Biosciences Announces Positive Results from Its First Study Evaluating a Clinical Target at Major Scientific MeetingApril 12th, 2018











